Quarterly report [Sections 13 or 15(d)]

Acquisition of CorHepta - Schedule of Fair Value of Consideration Transferred (Details)

v3.26.1
Acquisition of CorHepta - Schedule of Fair Value of Consideration Transferred (Details) - USD ($)
3 Months Ended
Feb. 21, 2026
Feb. 21, 2025
Mar. 31, 2026
Business Combination [Line Items]      
Shares vested 2,489,545   4,149,252
Fair Value, Recurring [Member]      
Business Combination [Line Items]      
Fair value of consideration     $ 7,338,719
Series of Individually Immaterial Asset Acquisitions | Fair Value, Recurring [Member]      
Business Combination [Line Items]      
Contingent consideration   $ 4,435,443  
CorHepta Pharmaceuticals [Member]      
Business Combination [Line Items]      
Fair value of consideration     $ 7,400,000
CorHepta Pharmaceuticals [Member] | Fair Value, Recurring [Member]      
Business Combination [Line Items]      
Fair value of fully vested shares   2,464,652  
Transaction costs incurred by the Company   438,624  
Fair value of consideration   $ 7,338,719  
CorHepta Pharmaceuticals [Member] | Common Stock      
Business Combination [Line Items]      
Shares vested   829,849 829,849
Shares representing contingent consideration   2,489,030 1,493,415
Share Price at Closing     $ 2.97